sny

French drug company Sanofi-Aventis (SNY) has finally made a deal to buy biotech company Genzyme (GENZ) for $20.1 billion, about $74 a share. Genzyme shareholders will get a contingent value right that represents potential future payments if Lemtrada, the company's multiple sclerosis drug, is a...

As European markets sell off, there are bargain stocks to be found overseas. We screened for beaten-down, big-cap multinationals in the eurozone (trading on U.S. exchanges) that should benefit from currency weakness.

Nearly 30 years after its discovery, AIDS still has no known cure. Researchers almost gave up hope of ever finding a vaccine. However, hopes were rekindled when a Phase III clinical trial involving more than 16,000 adult volunteers in Thailand demonstrated that an experimental HIV vaccine was safe...

AstraZeneca (AZN) has long hoped that its blood-thinner drug Brilinta was going to become a blockbuster. From the looks of things, the company may gets its wish. Back in May, the pharmaceutical company announced that its experimental heart drug Brilinta was more effective than Sanofi-Aventis...

Sanofi-Aventis (SNY) -- which only yesterday reported that its second-quarter profit surged 29.4 percent as net sales increased by 11.2 percent, beat estimates and raised 2009 guidance -- today announced it would purchase Merck & Co.'s (MRK) 50 percent stake in their Merial animal-health...

On Tuesday, the World Health Organization's top flu expert said the group is on the verge of declaring the first influenza pandemic in more than 40 years. Confirmed community spread in a second region beyond North America would trigger moving to phase 6, signifying a full-blown pandemic. It's...

If you opened any financial newspaper or site today, you couldn't have missed it: AstraZeneca (AZN) announced that its experimental heart drug Brilinta was more effective than Sanofi-Aventis (SNY) and Bristol-Myers Squibb Co's (BMY) blockbuster Plavix in the prevention of cardiovascular events,...

Investors have long heard of the problems plaguing Big Pharma, especially blockbuster drugs coming off patent in the near future, exposing them to competition from cheaper generics. A record number of drug sales will come off patent in the upcoming "patent cliff" arriving in 2010-2012. BusinessWeek...